Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31029597 | 0.95 | ALPL (0.46) | ALPLPIK3CAMTORATMATR | |
| SCHEMBL25778307 | 0.93 | PIK3CA (0.43) | ALPLPIK3CAMTORATMATR | |
| SCHEMBL109782 | 0.87 | ALPL (0.52) | ALPLPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL14860356 | 0.82 | ALPL (0.53) | ALPLPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL791103 | 0.81 | ALPL (0.48) | ALPLPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL798867 | 0.81 | ALPL (0.48) | ALPLPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL15560975 | 0.79 | CA1 (0.41) | ALPL | |
| SCHEMBL29556839 | 0.79 | ALPL (0.56) | ALPLPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL22447638 | 0.79 | ALPL (0.49) | ALPLPIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL789687 | 0.79 | ALPL (0.47) | ALPLPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-12-30 | — | — | US | disclosed |
| EP-4169917-B1 | QUINAZOLINE COMPOUNDS AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4169918-B1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3K FOR THE TREATMENT OF CANCER | INST MATERIA MEDICA CAMS (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-3560921-B1 | QUINAZOLINE COMPOUND, PREPARATION METHOD, APPLICATION AS PI3K INHIBITOR FOR THE TREATMENT OF CANCER, AND PHARMACEUTICAL COMPOSTION THEREOF | INST MATERIA MEDICA CAMS (CN) | 2024-08-14 | — | — | EP | disclosed |
| EP-4169917-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169918-A1 | QUINAZOLINE COMPOUND AND PREPARATION METHOD, APPLICATION, AND PHARMACEUTICAL COMPOSTION THEREOF | Institute of Materia Medica, Chinese Academy of Medical Sciences (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMYOF MEDICAL SCIENCES (CN) | 2023-04-13 | — | — | US | disclosed |
| US-11534443-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-12-27 | — | — | US | disclosed |
| WO-2014022128-A1 | PI3 KINASE MODULATORS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140038991-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | ALPL 937/4885PIK3CA 1232/4885MTOR 3521/4885 |
| US-12508263-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3R5, JAK1 | ALPL 3258/4885PIK3CA 1/4885MTOR 15/4885 |
| US-20230113478-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | ALPL 1635/4885PIK3CA 1/4885MTOR 27/4885 |
| US-11534443-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3CD, PDPK1 | ALPL 1635/4885PIK3CA 1/4885MTOR 27/4885 |
| US-12508264-B2 | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | PIK3CA, PIK3C2A, PIK3R5 | ALPL 2901/4885PIK3CA 1/4885MTOR 11/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | ALPL 2734/4885PIK3CA 995/4885MTOR 1752/4885 |
| US-20140038991-A1 | Protein Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K7 | ALPL 2923/4885PIK3CA 271/4885MTOR 131/4885 |
| US-20230110550-A1 | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | PIK3CA, PIK3CD, PDPK1 | ALPL 1635/4885PIK3CA 1/4885MTOR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.